美國Structural Bioinformatics, Inc. (SBI)
Structural Bioinformatics 公司是計算蛋白質組領域的全球領導者,希望將其蛋白質建模系統從基于Oracle和 Sun的基礎設施移植到一種新的解決方案上,最終決定用于IBM eServer xSeries服務器的Linux和Linux集群的 DB2,以及在Web上傳送事務的IBM WebSphere Application Server的解決方案。對于一系列計算,其Linux操作系統與IBM硬件和DB2的完美結合可以幫助他們將基準成本從每次計算28美元左右降低到1美元以下。
Structural Bioinformatics, Inc. (SBI) is a world leader in proteomics-driven drug discovery – the large-scale generation and use of protein structural information to accelerate the discovery and optimization processes.
SBI’s Genes to Leads technology, employing SBI’s proprietary DynaPharm and CombiLib technologies, offers a truly practical response to the wealth of new drug targets emerging from genomic sequencing efforts around the world for the human genome and the genomes of hundreds of infectious disease agents. Our technology reliably produces drug leads – in 60-120 days - starting with the sequence alone, with an efficiency that is more than 1,000-fold greater than state-of-the-art high throughput screening (HTS). The efficiencies in speed and cost are the direct result of the use of our underlying proprietary computational proteomics platform that allows us to generate X-ray quality protein structures at a fraction of the cost and time.